GFP has superior, proprietary chemistry for the preparation of Positron Emission Tomography (PET) imaging agents allowing more economic manufacture of purer PET imaging agents which have already been shown to have important roles in the diagnosis and management of cancer, heart disease and neurologic disease. The Company can market to the 900 cyclotron pharmacies worldwide.